CureVac (CVAC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CureVac has initiated Part B of its Phase 1 clinical trial for the mRNA-based cancer vaccine, CVGBM, aimed at treating patients with glioblastoma. This next phase will enroll up to 20 patients to further assess the vaccine’s safety, tolerability, and immunogenicity after Part A showed no dose-limiting toxicities. CVGBM represents the company’s innovative approach to developing cancer treatments using proprietary second-generation mRNA technology.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.